CSI Market
Sign In | Register

Progenics Pharmaceuticals Inc (PGNX) Annual Income Statement

Annual · GAAP · USD millions
Access PGNX quarterly income statements →
This page allows investors to track Progenics Pharmaceuticals Inc's income statement performance across multiple reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
2019 		(Dec 31 2018) (Dec 31 2017) (Dec 31 2016) (Dec 31 2015)
Revenues
Revenue From Contract With Customer Including Assessed Tax34.99
Total Revenue34.99
Costs & Expenses
Cost of Goods and Services Sold3.17
Gross Profit31.82
Selling, Administration, Marketing47.84
Research and Development Expense49.22
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Other Operating Expense / -Income0.00
Total operating costs including COS101.15
Operating income / -loss-66.16
Interest Expense2.38
Net Interest (-)Expense / Income-2.38
Other loss / -income0.00
Total costs & expenses103.52
Income & Taxes
Income / -loss before income taxes-68.54
Income taxes expenses / -benefit0.02
Income after income taxes-68.55
Net income / -loss of other equity0.00
Income / -loss from continuing operations-68.55
Non-controlling interests0.00
Net income / -loss-68.55
Income / -loss to shareholder-68.55
EBIT-66.16
EBITD-63.79
EBITDA-63.79
Earnings Per Share
Basic EPS (excl. extra items)-0.80
Basic Net EPS-0.80
Basic shares outstanding (Mill. of Units)85.61
Diluted Net EPS-0.80
Diluted average shares (Mill. of Units)85.61
4 historic quarters locked

Sign in to unlock the full Progenics Pharmaceuticals Inc income statement history.

Sign In Create Free Account

About PGNX Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.